Flowchart for patient inclusion.

*, including stomach cancer (n = 2), hepatocellular cancer (1), colon cancer (1), multiple myeloma (1), gastrointestinal stromal tumor (1), and ulcerative colitis (1). ADT, androgen deprivation therapy.</p

Effect of androgen-deprivation therapy (ADT) on the longitudinal serum uric acid (SUA) change in the whole population and post-matched population.

Effect of androgen-deprivation therapy (ADT) on the longitudinal serum uric acid (SUA) change in the whole population and post-matched population.</p

Longitudinal changes in serum urate (SUA) levels according to the subgroups.

Hyperuricemia (SUA ≥7.0 mg/dL), normouricemia (4.0≤ and <7.0 mg/dL), and hypouricemia (<4.0 mg/dL) were defined by using the baseline SUA levels. P values were corrected by the Bonferroni method. * p <0.05 between the baseline and 6-month time points; †, p <0.05 when compared between the surgery and ADT groups at each time point.</p

Effect of the interaction between a specific clinical factor and time on the longitudinal serum uric acid (SUA) levels.

Effect of the interaction between a specific clinical factor and time on the longitudinal serum uric acid (SUA) levels.</p

Baseline characteristics of the patients.

Baseline characteristics of the patients.</p

Influence of androgen deprivation therapy on serum urate levels in patients with prostate cancer: A retrospective observational study - Fig 2

Longitudinal changes in the serum urate (SUA, A), blood urea nitrogen (BUN, B), serum creatinine (C), total protein (D), albumin (E), and total cholesterol (F) levels. P values were corrected by the Bonferroni method. * p <0.05 between the baseline and 6-month time points; †, p <0.05 when compared between the surgery and ADT groups at each time point.</p